# Genflow Biosciences targets longevity market with gene therapy approach

- Link: https://www.directorstalkinterviews.com/genflow-biosciences-targets-longevity-market-with-gene-therapy-approach/4121253397
- Published: 2026-06-10T10:07:00+01:00
- Author: Amilia Stone

Longevity biotechnology is attracting investor attention as companies look for ways
to extend healthy lifespan and treat diseases linked to ageing. The sector, also
known as ageTech or longevity biotech, has seen rising investment in recent years
as research moves beyond general wellness and towards technologies that may be developed
into regulated medical products.

The main areas of research include epigenetic reprogramming, senolytics, artificial
intelligence-led drug discovery and nutraceuticals such as NAD+ boosters. Each approach
targets ageing from a different angle, but investors are increasingly focused on
projects with measurable results, clinical relevance and a clear route to market.

Genflow Biosciences is a British biotechnology company developing gene therapies
for age-related diseases. Its strategy is to target the biological mechanisms of
ageing using adapted versions of genes linked with longer and healthier lives.

The company’s work centres on SIRT6, a gene associated with DNA maintenance and 
metabolic regulation. SIRT6 is also linked with centenarians, which makes it relevant
to longevity research. Genflow is exploring whether this gene can be used in therapies
designed to slow biological ageing and improve health in later life. The potential
delivery method is intravenous infusion, although the products are not commercially
available. They remain in clinical development.

Genflow’s pipeline could have relevance in age-related liver disease, muscle loss
and eye health. These are sizeable areas of medical need as populations age, and
they give the company several potential routes for development. Its gene therapy
focus also helps separate it from companies selling supplements or pursuing less
clinically defined anti-ageing concepts.

The company is also developing veterinary versions of its products to study their
impact on biological ageing in pets. This may provide another way to test and understand
the technology, while also opening a possible additional market over time.

_**[Genflow Biosciences plc](https://www.directorstalkinterviews.com/company/genflow-biosciences-plc/genf.l)**(
LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in
Belgium focused on developing novel therapeutic approaches that potentially halt
or slow the aging process in humans and dogs supporting longer, healthier lives_

Share on:
